Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (2,2' Bis(4-pyridyl) 3h,3'h 5,5' Bibenzimidazole
2. 2,2'-dipyridin-4-yl-1h,1'h-5,5'-bibenzimidazole
3. Smt19969
1. 308362-25-6
2. Ridinilazole [inn]
3. Smt19969
4. Smt-19969
5. Ridinilazole [usan]
6. Chembl3753858
7. 5,5'-bi-1h-benzimidazole, 2,2'-di-4-pyridinyl-
8. 06dx01190r
9. 2,2'-di(pyridin-4-yl)-1h,1'h-5,5'-bibenzo[d]imidazole
10. 2-pyridin-4-yl-6-(2-pyridin-4-yl-3h-benzimidazol-5-yl)-1h-benzimidazole
11. 2,2'-di(pyridin-4-yl)-1h,1'h-5,5'-bi(benzimidazole)
12. P-pyben
13. Unii-06dx01190r
14. Ridinilazole [who-dd]
15. Schembl413723
16. Schembl17867397
17. Schembl19235713
18. Gtpl10853
19. Dtxsid101028337
20. Smt19969smt19969
21. Bdbm50134759
22. Mfcd28963972
23. Who 10075
24. Zinc113778168
25. Cs-6591
26. Db15308
27. Lx-0216
28. Hy-16753
29. D80826
30. Q25102246
31. 2,2'-dipyridin-4-yl-1h,1'h-5,5'-bibenzimidazole
32. 2,2'-bis(4-pyridyl)-3h,3'h-5,5'-bibenzimidazole
33. 2-(pyridin-4-yl)-6-[2-(pyridin-4-yl)-1h-1,3-benzodiazol-5-yl]-1h-1,3-benzodiazole
| Molecular Weight | 388.4 g/mol |
|---|---|
| Molecular Formula | C24H16N6 |
| XLogP3 | 3.9 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 3 |
| Exact Mass | 388.14364454 g/mol |
| Monoisotopic Mass | 388.14364454 g/mol |
| Topological Polar Surface Area | 83.1 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 524 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of Clostridium difficile infection
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Ridinilazole manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ridinilazole, including repackagers and relabelers. The FDA regulates Ridinilazole manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ridinilazole API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ridinilazole supplier is an individual or a company that provides Ridinilazole active pharmaceutical ingredient (API) or Ridinilazole finished formulations upon request. The Ridinilazole suppliers may include Ridinilazole API manufacturers, exporters, distributors and traders.
Ridinilazole Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ridinilazole GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ridinilazole GMP manufacturer or Ridinilazole GMP API supplier for your needs.
A Ridinilazole CoA (Certificate of Analysis) is a formal document that attests to Ridinilazole's compliance with Ridinilazole specifications and serves as a tool for batch-level quality control.
Ridinilazole CoA mostly includes findings from lab analyses of a specific batch. For each Ridinilazole CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ridinilazole may be tested according to a variety of international standards, such as European Pharmacopoeia (Ridinilazole EP), Ridinilazole JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ridinilazole USP).
LOOKING FOR A SUPPLIER?
